Sanofi pulls US lixisenatide filing
This article was originally published in Scrip
Executive Summary
Sanofi has voluntarily withdrawn its approval filing in the US for lixisenatide, its GLP-1 receptor agonist for type 2 diabetes, which is already approved in Europe, Japan and elsewhere under the brand name Lyxumia.